Health Tech Capitol | Cellectar Receives Orphan Drug Designation
16195
post-template-default,single,single-post,postid-16195,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cellectar Receives Orphan Drug Designation

19 Mar Cellectar Receives Orphan Drug Designation

Posted at 12:23h in Uncategorized by
0 Likes

Cellectar Biosciences has been granted orphan drug designation for its therapeutic, CLR 131, by the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for the treatment of neuroblastoma, the company announced today.

With the orphan drug designation, Cellectar Biosciences will receive seven-year market exclusivity benefits, increased engagement and assistance from the FDA, tax credits for certain research, research grants and a waiver of the new drug application user fee.

“The FDA’s granting of orphan drug designation for CLR 131 highlights the significant need for new treatments for children with neuroblastoma, and we believe that the targeted delivery of CLR 131 represents a promising novel approach to its treatment,” Cellectar Chief Medical Officer John Friend, M.D., said in a statement.

Read more at Madison Startups

No Comments

Sorry, the comment form is closed at this time.